India urology drugs market is anticipated to grow with an estimated CAGR in the forecast years FY2023-FY2027, on the grounds of increasing instances of urology diseases and urinary tract disorders. Increasing advancement in the pharmaceutical industry regarding urinary disease treatment is further driving the growth of the India urology drugs market in the upcoming five years.

Urology drugs are the pharmaceuticals that are used a treatment for urogenital conditions and diseases like urinary inconsistences, prostatic hyperplasia, and erectile dysfunctions. Urology is a part of healthcare sector that deals with the diseases of male and female urinary tract including reproductive organs. Urinary tract includes organs like kidney, ureters, bladder, and urethra.

Reproductive organs like penis, testes, scrotum, prostate, etc. involved in the conditions is also treated with use of urology drugs. Advancing pharmaceutical industry is consistently developing various therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin), Regurin and Sanctura (trospium chloride), Toviaz (fesoterodine), Vesicare (solifenacin), Sanctura (trospium).

Increasing Instances of Urinary Diseases Drive Market Growth

Rapidly increasing instances of urinary diseases and disorders in the country is anticipated to further drive the growth of the India urology drugs market in the upcoming five years. Approximately, 800 per million population in India have risk of chronic kidney diseases as per the report from 2020. The increasing risk of prostate cancer also supports the growth of the India urology drugs market in the next five years. Prostate cancer is the second leading site of cancer instances in the Indian males in metro cities like Delhi, Kolkata, Pune and Thiruvananthapuram.

Advancing Pharma Industry Supports Market Growth

Rapidly increasing advancement and product development is driving the growth of the India urology drugs market in the upcoming five years. Moreover, increasing investment in the research sector of the drug development is further anticipated to support the growth of the India urology drugs market in the next five years. Recent drug developments like antimuscarinic and beta-3-agonist drugs advances the growth of the India urology drugs market in the future five years.

Also, therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin), among other urology drugs are some of the advanced pharmaceutical products that are further substantiating the growth of the India urology drugs market in the forecast years.


Click here to download the sample

Market Segmentation

The India urology drugs market segmentation is based on drug class, type, application, distribution channel, competitional landscape, and regional distribution. Based on drug class, the market is further fragmented into anticholinergic/ antispasmodic agents, skeletal muscle relaxants, alpha blockers, and others. Also based on type, the market is further divided between original drugs and generic drugs.

Based on application, the market is segmented into benign prostatic hyperplasia (BPH), prostate cancer, urinary incontinence, kidney/bladder stone, erectile dysfunction, and others. The market segmentation based on distribution channel is bifurcated into hospital pharmacies, retail pharmacies, and online. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North India region, South India region, East India region, and West India region.

Company Profile

Astellas Pharma India Pvt Ltd, Endo Pharmaceuticals, Sanofi India, Pfizer Ltd., Innovexia Lifesciences, Salvus Pharma, Silhos Pharma Ltd., are some of the major market players in the country that lead the market growth analysis. New market players are also actively entering the market in the recent years and further strengthening the growth of the future market growth.

Attribute

Details

Base Year

FY2021

Historic Data

FY2017 – FY2020

Estimated Year

FY2022

Forecast Period

FY2023 – FY2027

Quantitative Units

Revenue in USD Million, volume in Thousand units and CAGR for FY2017 – FY2020 and FY2023 – FY2027

Report coverage

Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

  • Drug Class
  • Type
  • Application
  • Distribution Channel

Regional scope

North; South; East; West;

Key companies profiled

Astellas Pharma India Pvt Ltd, Endo Pharmaceuticals, Sanofi India, Pfizer Ltd., Innovexia Lifesciences, Salvus Pharma, Silhos Pharma Ltd.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, India Urology drugs market is segmented into following categories, in addition to the industry trends which have also been detailed below:

  • India Urology Drugs Market, By Drug Class:
    • Anticholinergic/ Antispasmodic Agents
    • Skeletal Muscle Relaxants
    • Alpha Blockers
    • Others
  • India Urology Drugs Market, By Type:
    • Original Drugs
    • Generic Drugs
  • India Urology Drugs Market, By Application:

o   Benign Prostatic Hyperplasia (BPH)

o   Prostate Cancer

o   Urinary Incontinence

o   Kidney/Bladder Stone

o   Erectile Dysfunction

o   Others

  • India Urology Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online
  • India Urology Drugs Market, By Region:
    • South
    • West
    • North
    • East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India urology drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

India Urology Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]

1.     Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on India Urology Drugs Market

4.    Executive Summary

5.    Voice of Customers

6.    India Urology Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value & Volume (Thousand Units)

6.2.  Market Share & Forecast

6.2.1.     By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, Others)

6.2.2.     By Type (Original Drugs v/s Generic Drugs)

6.2.3.     By Application (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others)

6.2.4.     By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)

6.2.5.     By Company (FY2021)

6.2.6.     By Region

6.2.6.1.         By State (Top 3 States)

6.3.  Product Market Map

7.    India Anticholinergic/Antispasmodic Urological Agents Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value & Volume (Thousand Units)

7.2.  Market Share & Forecast

7.2.1.     By Type

7.2.2.     By Distribution Channel

8.    India Skeletal Muscle Relaxants Urology Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value & Volume (Thousand Units)

8.2.  Market Share & Forecast

8.2.1.     By Type

8.2.2.     By Distribution Channel

9.    India Alpha Blockers Urology Drugs Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value & Volume (Thousand Units)

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By Distribution Channel

10.  Market Dynamics

10.1.              Drivers

10.2.              Challenges

11.  Market Trends & Developments

12.  Policy & Regulatory Landscape

13.  Pricing Analysis

14.  Import-Export Analysis

15.  India Economic Profile

16.  Competitive Landscape

16.1.              Competition Outlook

16.2.              Company Profiles

16.2.1.  Detailed Analysis of Marketing Activities of Top 3 Players Profiles

16.2.1.1.      Astellas Pharma India Pvt Ltd

16.2.1.2.      Endo Pharmaceuticals

16.2.1.3.      Sanofi India

16.2.1.4.      Pfizer Ltd.

16.2.1.5.      Innovexia Lifesciences

16.2.1.6.      Salvus Pharma

16.2.1.7.      Silhos Pharma Ltd.

17.  Go-To-Market Strategies (Covers detailed analysis of strategies to be followed for making market entry, what competitors are doing, etc.)

18.  Strategic Recommendations

19.  About Us & Disclaimer

(The company names can be customized according to the client’s requirements)

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]